Roles in PharmNovo: Chief executive officer, Business advisor and Director of the board.
Born: 1960.
Education: Bachelor’s degree in International Business Administration from the University of Lund.
Other current appointments: None.
Work experience: 30 years experience from International business in various industries and has vast experience in developing and transforming mid-size businesses. In 2003–2007 Per was VP Marketing & Sales for Nybron Flooring, European market leader in parquet flooring, with HQ in Switzerland and during 2008-2017 he was CEO at Elfa International with HQ in Malmö, Sweden.
Holdings: 25 000 shares.
Roles in PharmNovo: Founder, President, Chief scientific advisor and Director of the board.
Born: 1949
Education: PhD in Zoophysiology, Medical Physiology/Pharmacology, Histology.
Other current appointments: None.
Work experience: AstraZeneca 30 years. Visiting Fellow at University of Leicester 1.5 years, University of Iowa and University of Boston 1.5 year. Employed at AZ at the departments of Physiology, Bioscience, Pharmacology and Molecular Pharmacology. Principal scientist, group leader in IBS pain Molecular Pharmacology.
Holdings: 652 000 shares.
Roles in PharmNovo: Chief scientific officer and Director of the board.
Born: 1954
Education: Professor. Pharmacy graduate with a PhD in Neuropharmacology and worked as an industrial pharmacologist before returning to academic research at the Universities of Texas and Leicester.
Other current appointments: None
Work experience: 30 years of Academic and Industrial Research. Until August 2015, he was Professor of Pharmacology and former Head of Biomedical Sciences at the University of Nottingham Medical School.
Holdings: 250 000 shares
Role in PharmNovo: Consultant and toxicology advisor
Company: Toxicology Knowledge Team Sweden
Resumé: Kerstin has a PhD from Karolinska Institutet, Stockholm. Her research background is within the area of cell biology and DNA repair. She has 16 years of experience from toxicology at Safety Assessment, AstraZeneca, working as toxicology project leader and study director for in vivo toxicology studies, and within molecular toxicology. During the last 8 years she has been working at Toxicology Knowledge Team Sweden as a consultant and cofounder.
Role in PharmNovo: Clinical outsourcing lead.
Company: WIN Outsourcing Consult.
Resumé: Rikke is highly specialized and globally experienced within Pre-clinical and Clinical R&D, Business Development and Contract/Outsourcing Management and has worked in the CRO and Pharmaceutical industry within these fields for more than 25 years.
For almost two decades, she headed up the R&D Outsourcing & Contracts Management R&D function at Lundbeck where she was globally responsible for all R&D outsourcing matters covering contractual, operational and relationship related activities with all CROs/vendors as well as complex research collaborations agreements with academia. Rikke has significant experience in developing and executing a broad variety of outsourcing strategies and is a strong negotiator with a win-win approach to retaining positive relationships with all stakeholders.
Prior to her employment at Lundbeck, Rikke worked for five years within bio-analytical research and clinical development in hospital/academia settings. This was followed by four years of employment in a larger CRO (International Project Manager followed by setting up the CRO’s first South East Asia office working as Business Development Manager and Line Manager in Singapore).
Rikke has since 2013 been a Steering Committee member of the Pharmaceutical Contract Management Group (PCMG.org.uk) in Europe.
Role in PharmNovo: Regulatory affairs Lead
Company: Ozack ApS
Resumé: Ann Christine Korsgaard has for 25 years + headed up Global Regulatory Functions as Vice President in companies like Shionogi in UK, UCB in Belgium, and Genmab, Action Pharma, Actavis, and LEO Pharma in Denmark. Ann Christine has been the Global Regulatory Lead on numerous projects and led companies through strategic value creating interactions and meetings with the Health Authorities in especially Europe, US and Japan.
The many regulatory opportunities have taken her from small to bigger companies, from small molecules to biological/biotech, from EU to Global, from research organizations to generics, from early development to post-marketing activities, from HQ to affiliates, from authorities to industry, and from working in Denmark to Norway, Belgium, and UK.
